UT-HTL
14.4.2021 12:02:13 CEST | Business Wire | Press release
HTL , the worldwide leader in biotechnology solutions using hyaluronic acid (HA) and other biopolymers, and Echelon Biosciences Inc. , a U.S.-based global supplier of biochemical reagents, assays, and services to research and development laboratories, announced today their new distribution and product development partnership. The partnership will enable distribution of high-quality HA and glycosaminoglycan (GAG), and the co-development of novel GAG products.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210414005119/en/
The partnership provides academic research and pharmaceutical development laboratories’ expanded access to Good Manufacturing Practices (GMP)-grade, kit-packaged hyaluronic acid and glycosaminoglycan (GAG) products. By offering premium, clinical grade products to early-stage research investigators, the partnership seeks to bridge the gap between lab-based research, development and commercialization, and accelerate innovation worldwide.
“Innovation is at the heart of HTL’s DNA,” said HTL CEO Yvon Bastard . “This growth opportunity reinforces our mission and vision to apply science for increased bio-compatibility and improved health outcomes around the world.”
“This new partnership offers scientists and researchers the key technologies to develop innovative biopolymer solutions for new medical applications in aesthetics, ophthalmology, rheumatology, tissue engineering and drug delivery,” said Charles Ruban , HTL deputy CEO. “This is the true meaning of HTL’s tagline of ‘Beyond, together.’ HTL’s ambition is not only to grow its lead position in producing and distributing hyaluronic acid worldwide, but also to build tomorrow’s glycosaminoglycan-based solutions.”
“Echelon has been granted the opportunity to expand its market-leading HA assays and extra cellular matrix product line with the supply of HTL ’s hyaluronic acid and other GAG-derived products. HTL is recognized internationally for producing biopolymers of premium quality,” says Bert Israelsen , president of Echelon Biosciences . “Echelon offers our customers access to the latest innovative tools with unparalleled technical support, thereby fully enabling maximized creativity in basic and applied research. With its fermentation and organic synthesis platforms, HTL creates functionality and added value by developing chemically modified biopolymers tailored to specific needs.”
“This new partnership is a milestone in HTL’s expanding footprint in the North American market and with the U.S. medical community,” said Glenn Prestwich, Ph.D ., one of Echelon’s founders and now HTL’s exclusive science and innovation advisor for this market. By entrusting Echelon with the distribution of HTL’s hyaluronic acid and glycosaminoglycan products for research use, HTL aims to significantly increase its support and involvement in biopolymer research in the U.S. and worldwide, but also its research and development capacity.
“This new initiative demonstrates HTL’s commitment to invest in innovation in healthcare,” said Humberto C. Antunes , strategic advisor to HTL and former CEO of Galderma. “In the fields of health and wellness, the biotechnology ecosystem of innovation, incubators, and established and emerging companies are incredibly dynamic in the United States, Mexico and Canada. It means a huge growth potential for HTL products,” added Antunes.
About HTL
HTL is a biotechnology company, leading the way in the design and production of pharmaceutical grade hyaluronic acid and other innovative functional biopolymers for premium medical products. HTL serves the pharmaceutical and medical device industries worldwide, enabling them to transform lives of patients. HTL’s unsurpassed commitment to client partnership has been consistently proven in the marketplace. The company is recognized for supplying the highest quality products and continually investing in driving and supporting market growth. For over 25 years, its cutting-edge research and development has allowed to develop unique value-driven solutions to meet the innovation needs of its clients.
About Echelon Biosciences, Inc.
Based in Salt Lake City, Utah, Echelon Biosciences, was established in 1997 to supply synthetic lipid reagents for research and development. Since then, Echelon has successfully grown in scale and scope to include custom chemistry, peptides, and biological assays with over 700 catalog items in the fields of cell signaling, extracellular matrix, cancer drug discovery, and disease biomarkers.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210414005119/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sumitomo Corporation, SMBC Aviation Capital, Apollo and Brookfield Complete the Acquisition of Air Lease Corporation8.4.2026 15:13:00 CEST | Press release
Sumitomo Corporation, SMBC Aviation Capital, Apollo-managed funds (“Apollo”) and Brookfield today announced that they have completed the previously announced acquisition of Air Lease Corporation (“Air Lease”) and have renamed the business Sumisho Air Lease Corporation (“Sumisho Air Lease”). This transformational transaction improves the financial position of the business with long term support and aviation expertise from co-investors Sumitomo Corporation, SMBC Aviation Capital, Apollo and Brookfield. Sumisho Air Lease’s strong foundation as an established aircraft lessor, supported by SMBC Aviation Capital’s industry‑leading capabilities as servicer, creates a platform with the scale and financial strength needed to meet the fast‑changing and increasingly complex requirements of airline customers. Sumisho Air Lease will also benefit from the deep expertise and long-standing commitment that both Sumitomo Corporation and SMBC Aviation Capital bring to the global aviation leasing sector.
Sitetracker Launches Scout, an Agentic AI Platform Purpose-Built for Critical Infrastructure8.4.2026 15:00:00 CEST | Press release
Sitetracker, the leading Asset Lifecycle Management platform for critical infrastructure, today announced the launch of Scout, its new Agentic AI platform designed to help infrastructure owners, operators, and contractors gain deep insights and drive automation within their operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260408923336/en/ Scout, ready for real work As your AI analyst and agent, Scout is ready to work on day 1. Scout provides clarity when decisions are forming and momentum when action is required. It surfaces risk, synthesizes information, and helps accelerate execution by connecting data and driving action. Scout creates operational intelligence and turns it into action all in a secure environment that protects data sovereignty. “Our customers are looking to create compounding competitive advantages,” said Giuseppe Incitti, Chief Executive Officer of Sitetracker. “Scout delivers by providing easy t
Westinghouse Hosts Annual VVER Fuel Forum with Customers8.4.2026 15:00:00 CEST | Press release
Westinghouse currently has fuel supply contracts with all the European VVER operators Westinghouse and MVM Paks Nuclear Power Plant (NPP) recently co-hosted the VVER Fuel Forum in Budapest to share insights and plans for the continued deployment of VVER-1000 and VVER-440 fuel in operating reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260408646373/en/ Participants to the VVER Fuel Forum Péter János Horváth, CEO of MVM Paks, welcomed all the participants, highlighting that Hungary is ending two decades of single supplier fuel dependency thanks to the agreement recently signed with Westinghouse to supply the VVER-440 NOVA E-6 fuel design. Six customers presented the progress made and positive outcomes achieved in the past years with the introduction of Westinghouse fuel into mixed cores with resident fuel in their reactors: Energoatom has extensive experience with Westinghouse VVER-440 and VVER-1000 fuel, currently u
Virica Biotech and FUJIFILM Biosciences Collaborate Under the Canada–Japan Co‑Innovation Program to Advance AAV Production Enhancers8.4.2026 15:00:00 CEST | Press release
Efficient production of Adeno-Associated Virus (AAV) vectors at scale for in vivo gene therapies remains a key bottleneck for broad patient access and sustainable manufacturing costs.Virica and FUJIFILM Biosciences will co-develop an off-the-shelf enhancer–media solution to boost AAV yields and process robustness in FUJIFILM Biosciences BalanCD® HEK293 system. Virica Biotech (“Virica”), a cell enhancer company specializing in Viral Sensitizers (VSE™) for viral vector manufacturing, today announced it is receiving advisory services and funding from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP), under the Canada–Japan Corporate Co-Innovation Program for a collaboration with FUJIFILM Biosciences. The collaboration will focus on optimizing a VSE™ formulation for FUJIFILM Biosciences BalanCD HEK293 media to support academic and commercial AAV producers globally. AAV vectors are a cornerstone of in vivo gene delivery for gene therapies, but they re
Barilla Confirmed as the World’s Leading Food Company for Reputation - Ranking 9th Overall Globally8.4.2026 14:42:00 CEST | Press release
GLOBAL REPTRAK®100 2026For the third consecutive year, Barilla is confirmed as the world’s leading food company in the Global RepTrak® 100 and enters the overall Top 10 of global companies.The Group ranks 9th overall, up 16 positions compared to 2025. For the third year in a row, Barilla is confirmed as the world’s leading company in the food sector for reputation in the Global RepTrak® 100 ranking conducted by RepTrak, which since 1999 has annually analyzed the companies with the strongest reputations worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260407912080/en/ In the 2026 ranking, the Group reaches 9th place overall, moving up 16 spots compared to 2025 (ranked at 25th) and entering the global Top 10, confirming the company’s steady reputation‑building journey developed over the years. This result reflects Barilla’s ability to combine product quality, industrial vision and social responsibility – factors that
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom